Thiazolidinediones (TZD) are a relatively new class of insulin-sensitizing agents used to treat type 2 diabetes mellitus (T2DM) and have also been shown to reduce risk for, or even prevent, T2DM in at-risk individuals. However, 30-40% of subjects do not respond to TZD therapy. TZDs are agonists for peroxisome proliferator-activated receptor-g2 (PPARG2). We hypothesize that variation in the gene encoding for PPARG2 may mediate response to TZDs. We also hypothesize that variants in genes encoding for proteins involved in the metabolism of TZDs or in the TZD-stimulated pathway may also contribute to response to drug. We propose the following series of studies to address these hypotheses. First, we propose a three- month open-label pioglitazone (PIO) trial in Latinas with previous gestational diabetes (GDM) to increase the sample size of our existing data. Women will be placed on PIO (45 mg/d) for three months and body composition, insulin sensitivity, and b cell function will be assessed at baseline and 3-months. Lack of response to PIO will be determined by a non-significant improvement in insulin sensitivity. This trial will provide additional data to test association between genetic variants and TZD response, and TZD-induced changes in metabolic phenotypes. Second, we propose to genotype genetic variants in PPARG shown to be associated with response to troglitazone and to screen candidate genes; three cytochrome P-450 genes (CYP2C8, CYP2C9, and CYP3A4), which are involved in PIO metabolism; retinoid X receptor-a (RXRA) a critical co-factor for PPARG; and peroxisome proliferator-activated receptor-g coactivatoMa (PPARGC1A) a critical regulator of the PPARG-stimulated pathway. Third, we propose specific genetic analyses to test variants genotyped in the second aim for association with response to PIO and PlO-induced changes in phenotypes. We propose methods to control for potential population stratification and multiple comparisons. We also propose exploratory analyses to examine the effect of multiple genetic variants (within genes and between genes) on response to PIO. Our long-term goal is to understand the genetic architecture of TZD response and to develop approaches to predict who will or will not respond to TZDs. This will help clinicians to avoid interventions that have a low probability of success in a given patient with T2DM. ? ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK069922-02
Application #
7344774
Study Section
Kidney, Nutrition, Obesity and Diabetes (KNOD)
Program Officer
Mckeon, Catherine T
Project Start
2007-02-01
Project End
2010-01-31
Budget Start
2008-02-01
Budget End
2009-01-31
Support Year
2
Fiscal Year
2008
Total Cost
$449,243
Indirect Cost
Name
University of Southern California
Department
Public Health & Prev Medicine
Type
Schools of Medicine
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Dimas, Antigone S; Lagou, Vasiliki; Barker, Adam et al. (2014) Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity. Diabetes 63:2158-71
Watanabe, Richard M (2011) Statistical issues in gene association studies. Methods Mol Biol 700:17-36
Black, Mary Helen; Watanabe, Richard M (2011) A principal components-based clustering method to identify variants associated with complex traits. Hum Hered 71:50-8
Voight, Benjamin F; Scott, Laura J; Steinthorsdottir, Valgerdur et al. (2010) Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 42:579-89
Saxena, Richa; Hivert, Marie-France; Langenberg, Claudia et al. (2010) Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 42:142-8
Watanabe, Richard M (2010) The genetics of insulin resistance: Where's Waldo? Curr Diab Rep 10:476-84
Perry, John R B; Weedon, Michael N; Langenberg, Claudia et al. (2010) Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes. Hum Mol Genet 19:535-44
Prokopenko, Inga; Langenberg, Claudia; Florez, Jose C et al. (2009) Variants in MTNR1B influence fasting glucose levels. Nat Genet 41:77-81
Chen, Wei-Min; Erdos, Michael R; Jackson, Anne U et al. (2008) Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose levels. J Clin Invest 118:2620-8